BRIEF published on 11/11/2025 at 08:05, 23 days 23 hours ago Medincell élargit le rôle du Dr Grace Kim pour stimuler la croissance du capital américain Biotechnologie Medincell Stratégie Pharmaceutique Dr Grace Kim Croissance Du Capital Américain
BRIEF published on 11/11/2025 at 08:05, 23 days 23 hours ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
PRESS RELEASE published on 11/11/2025 at 08:00, 23 days 23 hours ago Informations privilégiées / Autres communiqués Medincell nomme le Dr Grace Kim au poste de Chief Strategy Officer, U.S. Finance, pour renforcer la croissance de son capital aux États-Unis. Découvrez son parcours et son rôle clé chez Medincell Croissance Chief Strategy Officer Medincell Dr Grace Kim Capital Américain
PRESS RELEASE published on 11/11/2025 at 08:00, 23 days 23 hours ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 29 days 17 hours ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
BRIEF published on 11/05/2025 at 13:51, 29 days 17 hours ago Croissance continue pour Medincell et nouvelles perspectives avec l'Olanzapine LAI Schizophrénie Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 29 days 17 hours ago Informations privilégiées / Autres communiqués Medincell annonce la poursuite de la croissance d'UZEDY® et la préparation du dépôt de l'Olanzapine LAI sur le marché américain par Teva Pharmaceuticals Croissance Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 29 days 17 hours ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
BRIEF published on 10/10/2025 at 22:16, 1 month 25 days ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
BRIEF published on 10/10/2025 at 22:16, 1 month 25 days ago La FDA approuve UZEDY pour le traitement du trouble bipolaire de type I chez l'adulte Approbation De La FDA Traitement De Santé Mentale UZEDY Trouble Bipolaire I Risperidone
Published on 12/05/2025 at 02:35, 4 hours 51 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 26 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 21 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 26 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 26 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 56 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 35 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 1 minute ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 11 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 11 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 26 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 26 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 41 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 41 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
